We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.22B
1-Year Est. Return 242.83%
This Fund
S&P 500
This Quarter Est. Return
-9.72%
1 Year Est. Return
+242.83%
3 Year Est. Return
+1,579.88%
5 Year Est. Return
+1,852.28%
10 Year Est. Return
–
AUM
$637M
AUM Growth
-$173M
Cap. Flow
-$12.8M
Cap. Flow %
-2%
Top 10 Hldgs %
65.73%
Holding
51
New
1
Increased
5
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
SRZN icon
Surrozen
SRZN
+$2.81M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$2.74M
3
TNGX icon
Tango Therapeutics
TNGX
+$2.4M
4
ALLK
Allakos
ALLK
+$2.31M
5
ELEV
Elevation Oncology
ELEV
+$11

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$7.21M
2
JANX icon
Janux Therapeutics
JANX
+$5.64M
3
CHFW.U
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
+$3.12M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$2.48M
5
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
+$2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.27%
2 Miscellaneous 5.48%
3 Financials 1.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LENZ
1
LENZ Therapeutics
LENZ
$130M
$122M 19.11%
1,061,660
– –
NKTX icon
2
Nkarta
NKTX
$206M
$56.6M 8.88%
2,034,703
– –
KDNY
3
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$43.1M 6.76%
3,376,888
+208,500
+7% +$2.74M
TIL icon
4
Instil Bio
TIL
$48.7M
$38.3M 6.02%
107,270
– –
FMTX
5
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$36.3M 5.7%
1,565,526
-3
-0% -$71
STRO icon
6
Sutro Biopharma
STRO
$259M
$31.7M 4.97%
167,558
– –
CNTA
7
DELISTED
Centessa Pharmaceuticals
CNTA
$25.7M 4.03%
1,537,533
– –
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$23.8M 3.73%
1,462,834
-662,537
-31% -$7.21M
RAIN
9
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$23.5M 3.69%
1,571,379
-65,929
-4% -$1.12M
ALLK
10
DELISTED
Allakos
ALLK
$18.2M 2.86%
172,089
+25,830
+18% +$2.31M
ALLK
11
CALL
DELISTED
Allakos
ALLK
$17.8M 2.79%
168,200
+85,200
+103% +$7.61M
RXRX icon
12
Recursion Pharmaceuticals
RXRX
$1.71B
$17.3M 2.72%
752,939
-22,644
-3% -$642K
NVAX icon
13
CALL
Novavax
NVAX
$1.54B
$17.1M 2.69%
82,600
-116,000
-58% -$25.6M
ACRS icon
14
Aclaris Therapeutics
ACRS
$783M
$14.3M 2.24%
794,171
– –
SWTX
15
DELISTED
SpringWorks Therapeutics
SWTX
$10.8M 1.69%
169,852
– –
ICPT
16
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$9.51M 1.49%
640,688
– –
BOLT icon
17
Bolt Biotherapeutics
BOLT
$6.99M
$9.33M 1.46%
36,873
– –
TNGX icon
18
Tango Therapeutics
TNGX
$3.94B
$9.05M 1.42%
700,000
+200,000
+40% +$2.4M
JANX icon
19
Janux Therapeutics
JANX
$993M
$8.91M 1.4%
411,871
-196,078
-32% -$5.64M
SYRS
20
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$8.62M 1.35%
218,920
– –
ELEV
21
DELISTED
Elevation Oncology
ELEV
$7.26M 1.14%
932,240
+1
+0% +$11
SYRE icon
22
Spyre Therapeutics
SYRE
$8.04B
$7.03M 1.1%
35,349
– –
DBTX
23
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$6.37M 1%
826,422
– –
NVAX icon
24
Novavax
NVAX
$1.54B
$6.25M 0.98%
30,160
– –
VRNA
25
DELISTED
Verona Pharma
VRNA
$6.09M 0.96%
1,111,112
– –
1
2 3

Similar funds

MWA
Monograph Wealth Advisors Manhattan Beach, California $1.22B AUM 24.22% 1-Year Est. Return
SFP
Shepherd Financial Partners Winchester, Massachusetts $1.22B AUM 28.54% 1-Year Est. Return
OCM
Once Capital Management New York $1.22B AUM 87.6% 1-Year Est. Return
TCM
Tributary Capital Management Omaha, Nebraska $1.22B AUM 44.12% 1-Year Est. Return
TCM
Thames Capital Management Roseland, New Jersey $1.22B AUM 391.75% 1-Year Est. Return
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
GGI
Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return
SL
Salomon & Ludwin Richmond, Virginia $1.22B AUM 19.42% 1-Year Est. Return

Samsara BioCapital's Q3 2021 Portfolio in Review

As of Q3 2021, Samsara BioCapital held 51 positions worth $637M, down 21% from $810M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Samsara BioCapital's Q3 2021 filing shows 1 new, 5 increased, 8 reduced and 3 closed positions. Its largest new stake was Surrozen: 20,000 shares worth $2.12M. The largest sale was IVERIC bio, Inc. Common Stock, an estimated $7.21M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Miscellaneous and Financials.

  • Samsara BioCapital's largest Q3 2021 buy was Surrozen: 20,000 shares worth $2.12M.
  • Samsara BioCapital added most to Chinook Therapeutics, Inc. Common Stock in Q3 2021, an estimated $2.74M increase.
  • Samsara BioCapital's biggest Q3 2021 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $7.21M.
  • Samsara BioCapital fully exited Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third in Q3 2021, selling an estimated $3.12M.
  • Samsara BioCapital's ten largest holdings make up 66% of its $637M portfolio in Q3 2021.
  • Samsara BioCapital opened 1 new position and closed 3 in Q3 2021.
  • Samsara BioCapital's portfolio value fell 21% quarter-over-quarter to $637M.

Based on Samsara BioCapital's 13F filing for Q3 2021, filed 15 Nov 2021.